Excited to present our PSMA-BAT trial poster today at #ESMO23@myESMO! Meet us at 12 pm to know more about biomarkers in pts with mCRPC treated with Bipolar Androgen Therapy (BAT).
Oncological data is lacking for the majority of tumors in LATAM. Our group @LACOG_group, lead by @DiogoAssed published the largest cohort of patients with germ-cell tumors treated in Latin America. Are the outcomes comparable to developed countries? https://t.co/UWHSFW3vql
CDK12 alterations confer an aggressive phenotype to PCa. Our paper describes successful cases treated with DNA damaging therapies and immunotherapies in CDK12-altered mCRPC, potentially stimulating future studies evaluating this combinations. 👇https://t.co/wNFzUXphNC
👉🏻 Just out: Our Case Series raise the hypothesis of a possible association of the 🧬MITF p.E318K pathogenic variant with an increased risk of breast cancer.
#oncogenetics#breastcancer@OncoAlert
A oncologista @alineblara, do @hsiriolibanes, é 1ª autora de estudo publicado no JCO Global Oncology (LACOG 0420) que avaliou o impacto da pandemia de COVID-19 em ensaios clínicos em oncologia na América Latina. O oncologista @DiogoAssed é o autor sênior - https://t.co/jEex89WtSD
COVID-19 has been causing a significant impact on oncology clinical trials. How deep were trials in Latin America affected and in which aspects can oncology research improve based on these results?https://t.co/9zB5xFpKUQ
@DiogoAssed@jardim_denis@LacogG @JGO_ASCO @ASCO_pubs
Interesting review on promising novel AR directed therapies for advanced prostate cancer. Several new and different potential approaches to tackle the AR pathway. Thanks @EAntonarakis and Pedro Isaacson! @jardim_denis@SoaresAndrey@FabioSchutz78
Quatro vagas disponíveis para o programa de Oncologia Clínica! Inscrições através do link https://t.co/x6AsEATvPT | Our MedOnc fellowship selection is about to happen! #EdTwitter#Oncology#Fellowship @HSL_RTFellows @hsiriolibanes